secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261719
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna secures up to $150M debt facility from Oxford Finance; SPS data readout accelerated
--------------------------------------------------------------------------------

- Non-dilutive term loan facility of up to $150M; initial draw of $25M on Nov 3, 2025.
- Loan matures Oct 1, 2030; floating interest at 1M SOFR + 5.00% (floor 3.75%); interest-only to Nov 2028/2029.
- Cash runway extended into 2027, supporting SPS BLA filing and MG Phase 3 trial.
- Topline registrational Phase 2 SPS data now expected early 2026 (narrowed from 1H 2026); BLA filing 1H 2026.
- MG Phase 3 enrollment to start by year-end 2025; updated Phase 2/3 data expected 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525261719/0001193125-25-261719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525261719/kytx-20251102.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer